BOSTON and LONDON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced...
Researchers to study the potential of SCY-247 to fight Candida auris (C.auris), a multidrug-resistant pathogen named as an “urgent threat”...
Presentation highlights a novel target identified for Alzheimer’s disease using Cerevance’s proprietary NETSseq platform Cerevance’s THIK-1 targeting inhibitor, C101248, demonstrated...
AGOURA HILLS, Calif., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer...
New York, NY, and Tel Aviv, ISRAEL, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical...
Company is Opting to Increase Study Size to 400 due to Fast Enrollment PaceCARSON CITY, Nev., Nov. 29, 2022 (GLOBE...
Regulatory clearance lays key technological and regulatory foundation for BT BeaMedical’s vision of revolutionizing treatment options in neurosurgery, oncology, and...
Las Vegas, Nevada, Nov. 24, 2022 (GLOBE NEWSWIRE) -- Founded by a team of experts with over 60 years of...
VANCOUVER, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (CSE: CMND), (FSE: CWY) (“Clearmind” or the "Company"),...
Las Vegas, Nevada, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a...
New York, NY, and Tel Aviv, ISRAEL, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB:...
Top line data from a one-month TB006 treatment regimen shows improvements in Clinical Dementia Rating-Sum of Boxes (CDR-SB) in patients,...
ONCR-719 is uniquely engineered to use the Epidermal Growth Factor Receptor (EGFR/EGFRvIII) for viral entry, which is highly expressed in...
CAN-3110 designed to limit replication and promote anti-tumor response to tumor cells while protecting healthy tissueNo dose-limiting toxicities observed in...
Phase 2 clinical trial investigating KP1077 in patients with IH expected to initiate prior to year-end 2022 CELEBRATION, Fla., Nov....
Phase 3 data for elafibranor in primary biliary cholangitis (PBC) expected in 2Q23Expanded pipeline now covers five therapeutic areas with...
BRISBANE, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class...
VANCOUVER, British Columbia, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed...
Glen Rock, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI) (“RespireRx” or the “Company”), a...
SOUTH SAN FRANCISCO, Calif., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated...